WHAT IS CLAIMED IS:

1. The compound which has the structure



2. The compound which has the structure



3. The compound which has the structure



4. The compound which has the structure



5. The compound which has the structure



6. The compound which has the structure:



wherein R is straight or branched alkyl of 1 to 10 carbon atoms, alkenyl of 2 to 10 carbon atoms, cycloalkyl of 3 to 10 carbon atoms and cycloalkenyl of 3 to 10 carbon atoms.

7. The compound according to claim 6 where R is $-CH_2CH_2CH_3$, $-CH(CH_3)_2$, $-CH_2CH_2CH_2CH_3$, or $-CH_2CH_2CH_2CH_2CH_3$.

8. A method of treating a warm-blooded animal affected by bacterial infections, which method comprises administering to said warm-blooded animal an effective amount of a compound of claim 1.

9. A method of treating a warm-blooded animal affected by bacterial infections, which method comprises administering to said warm-blooded animal an effective amount of a compound of claim 2.

10. A method of treating a warm-blooded animal affected by bacterial infections, which method comprises administering to said warm-blooded animal an effective amount of a compound of claim 3.

11. A method of treating a warm-blooded animal affected by bacterial infections, which method comprises administering to said warm-blooded animal an effective amount of a compound of claim 4.

12. A method of treating a warm-blooded animal affected by bacterial infections, which method comprises administering to said warm-blooded animal an effective amount of a compound of claim 5.

13. A method of treating a warm-blooded animal affected by bacterial infections, which method comprises administering to said warm-blooded animal an effective amount of a compound of claim 6.

14. A pharmaceutical composition comprising an effective amount of a compound of claim 1 together with a pharmaceutically acceptable carrier.

15. A pharmaceutical composition comprising an effective amount of a compound of claim 2 together with a pharmaceutically acceptable carrier.

16. A pharmaceutical composition comprising an effective amount of a compound of claim 3 together with a pharmaceutically acceptable carrier.

17. A pharmaceutical composition comprising an effective amount of a compound of claim 4 together with a pharmaceutically acceptable carrier.

18. A pharmaceutical composition comprising an effective amount of a compound of claim 5 together with a pharmaceutically acceptable carrier.

19. A pharmaceutical composition comprising an effective amount of a compound of claim 6 together with a pharmaceutically acceptable carrier.

20. A pharmaceutical or disinfectant composition which contains an effective antimicrobial, antiseptic or disinfectant amount of the compound of claim 1 as an active ingredient.

21. A pharmaceutical or disinfectant composition which contains an effective antimicrobial, antiseptic or disinfectant amount of a compound of claim 2 as an active ingredient.

22. A pharmaceutical or disinfectant composition which contains an effective antimicrobial, antiseptic or disinfectant amount of a compound of claim 3 as an active ingredient.

23. A pharmaceutical or disinfectant composition which contains an effective antimicrobial, antiseptic or disinfectant amount of a compound of claim 4 as an active ingredient.

24. A pharmaceutical or disinfectant composition which contains an effective antimicrobial, antiseptic or disinfectant amount of a compound of claim 5 as an active ingredient.

25. A pharmaceutical or disinfectant composition which contains an effective antimicrobial, antiseptic or disinfectant amount of a compound of claim 6 as an active ingredient.

26. A process for the preparation of antibiotics Cyan-416 A, Cyan-416 B, Cyan-416 C, Cyan-416 D, or Cyan-416 E, which comprises cultivating *Acremonium sp.* designated *NRRL30631* or a mutant thereof under aerobic conditions in a sterile liquid medium containing assimilable sources of carbon, nitrogen and inorganic anion and cation salts, until substantial antibiotic activity is imparted to said medium by the production of Cyan-416 A, Cyan-416 B, Cyan-416 C, Cyan-416 D, or Cyan-416 E, recovering and isolating said antibiotics.

27. The process according to claim 26 wherein said recovered antibiotics Cyan-416 A, Cyan-416 B, Cyan-416 C, Cyan-416 D, and Cyan-416 E are separated and purified by high pressure liquid chromatography, HPLC.

28. A process for the preparation of esters of the formula



wherein R is straight or branched alkyl of 1 to 10 carbon atoms, alkenyl of 2 to 10 carbon atoms, cycloalkyl of 3 to 10 carbon atoms and cycloalkenyl of 3 to 10 carbon atoms which comprises reacting an anhydride, $(R\text{-}C(O)\text{-})_2O$ where R is straight and branched alkyl of 1 to 10 carbon atoms, alkenyl of 2 to 10 carbon atoms, cycloalkyl of 3 to 10 carbon atoms and cycloalkenyl of 3 to 10 carbon atoms in the presence of boron trifluoride diethyl etherate ($BF_3\text{-}Et_2O$) at about 0° C with Cyan-416B of the formula



to afford an ester of the formula



29. A process for the preparation of Cyan-416B of the formula



which comprises hydrolyzing with acid a compound of the formula



where R is straight and branched alkyl of 1 to 10 carbon atoms, alkenyl of 2 to 10 carbon atoms, cycloalkyl of 3 to 10 carbon atoms and cycloalkenyl of 3 to 10 carbon atoms to give a compound of the formula



30. The process according to claim 29 wherein the acid is hydrochloric acid.

31. A process for the preparation of antibiotics Cyan-416A, Cyan-416B, Cyan-416C, Cyan-416D, or Cyan-416E, which comprises cultivating *Acremonium sp.* Designated NRRL30631 or a mutant thereof on moist milk filter paper on the surface of a solid agar medium containing malt extract, peptone and yeast extract and incubated under stationary conditions at about 22°C until substantial antibiotic activity is imparted to said medium by the production of Cyan-416A, Cyan-416B, Cyan-416C, Cyan-416D, or Cyan-416E, recovering and isolating said antibiotics.

32. The process according to claim 31 wherein said recovered antibiotics Cyan-416A, Cyan-4156B, Cyan-416C, Cyan-416D, and Cyan-416E are separated and purified by high pressure liquid chromatography, HPLC.